Regeneron Pharmaceuticals Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Direxion Daily Semiconductor Bear 3X Shares trades at $43.68. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| REGN | SOXS | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $1.61K |
52-Week Low | $545.46 | $32.50 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $53.99, down 1.64% with a bearish moving average signal but bullish overall technical outlook. The ETF provides 3x leveraged inverse exposure to semiconductors, recently benefiting from sector volatility. A 1:10 stock split is scheduled for July 26, 2026, following a $0.04 dividend payment in June. Recent news highlights SOXS's surge during semiconductor sell-offs, with the ETF gaining attention as a tactical instrument amid AI-driven chip market fluctuations.
SOXS offers leveraged inverse exposure to semiconductor stocks, presenting high-risk, tactical opportunities during sector downturns. The bullish technical signal contrasts with overbought RSI readings, suggesting potential near-term volatility. Key risks include leverage decay, sector reversal momentum, and dependence on semiconductor market weakness. Investors should approach SOXS as a short-term hedging tool rather than a long-term holding due to its inverse structure and high volatility.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →